Literature DB >> 11695287

[Transfusion of fresh frozen plasma (FFP): audit of prescriptions].

H Beloeil1, M Brosseau, D Benhamou.   

Abstract

OBJECTIVE: To review fresh frozen plasma (FFP) prescriptions and compare their validity to the legal french guidelines (law of the 12/03/91). STUDY
DESIGN: Assessment of all prescriptions has been carried out by a multidisciplinary committee. PATIENTS: All the adults transfused with FFP over one year in a teaching hospital.
METHODS: Following each head of department's agreement and following a written notice to all prescribers within the hospital to inform them of the undergoing study and its methodological validation by the board of quality experts, each delivery of FFP was followed by a questionnaire addressed to the prescriber. A board of experts then assessed the significance of the prescription in accordance with the legal requirements after reviewing each medical file.
RESULTS: 144 prescriptions to 89 patients were assessed: 23% were judged inappropriate by the experts and 6% did not respect the law. The inappropriate transfusions distribute as follows: intensive care patients (73% of which 80% in multiple organ failure (MOF) and 20% in haemorrhagic shock), cirrhotic patients (12%), patients treated with vitamin K antagonists (12%), obstetric patients (3%). Nine percent of the appropriate transfusions were judged in insufficient volume. The hospital mortality rate was 48%. Among prescribers, 59% were not aware of the law.
CONCLUSION: A significant proportion of FFP transfusions is inappropriate. This study, which is the first step of a quality assurance program, will be followed by local recommendations for clinical practice. The current standards of prescribing FFP are more restrictive than those defined in the legal french guidelines.

Entities:  

Mesh:

Year:  2001        PMID: 11695287     DOI: 10.1016/s0750-7658(01)00462-2

Source DB:  PubMed          Journal:  Ann Fr Anesth Reanim        ISSN: 0750-7658


  5 in total

1.  Tuscan study on the appropriateness of fresh-frozen plasma transfusion (TuSAPlaT).

Authors:  Giancarlo Maria Liumbruno; Maria Laura Sodini; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2007-04       Impact factor: 3.443

2.  An audit of fresh frozen plasma usage in a tertiary trauma care centre in north India.

Authors:  Neha Agarwal; Arulselvi Subramanian; Ravindra Mohan Pandey; Venencia Albert; Sulekha Karjee; Vedanand Arya
Journal:  Indian J Hematol Blood Transfus       Date:  2013-05-15       Impact factor: 0.900

3.  An audit of fresh frozen plasma usage and effect of fresh frozen plasma on the pre-transfusion international normalized ratio.

Authors:  S A Shinagare; N N Angarkar; S R Desai; M R Naniwadekar
Journal:  Asian J Transfus Sci       Date:  2010-07

4.  Audit of the clinical use of fresh-frozen plasma in Umbria: study design and results of the pilot phase.

Authors:  Alfonso Iorio; Michela Basileo; Emanuela Marchesini; Gian Paolo Palazzesi; Mario Materazzi; Mauro Marchesi; Antonella Esposito; Lucio Pellegrini; Antonella Germani; Lauretta Rocchetti; Carla Maria Silvani
Journal:  Blood Transfus       Date:  2008-10       Impact factor: 3.443

5.  Current Practice in FFP Preparation and Use in Greece: A National Survey

Authors:  Aspasia Argyrou; Serena Valsami; Abraham Pouliakis; Maria Gavalaki; Antonis Aggelidis; Vasiliki Voulgaridou; Vasiliki Pliatsika; Theofanis Adraktas; Andreas Papachronis; Chrysoula Alepi; Vasiliki Giannopoulou; Panagiotis Siourounis; Sofia Tsagia; Georges Martinis; Eftihia Kontekaki; Eleftheria Zervou; Spiridon Koliofotis; Elias Kyriakou; Athina Mougiou; Lempousi Dimitra; Afrodite Chairopoulou; Aggeliki Tsakania; Maria Baka; Ioanna Apostolidou; Dimitra Moschandreou; Anastasia Livada; Marianna Politou; Fragoula Roussinou; Christina Pappa; Vasiliki Koika; Niki Vgontza; Anthippi Gafou; Ioanna Dendrinou; Fotini Sakellaridi; Lampothea Labrianou; Zafeiria Alexandropoulou; Vasiliki Sochali; Kostas Malekas; Areti Skordilaki; Georgia Kakava; Konstantinos Lebesopoulos; Konstantinos Stamoulis; Elisavet Grouzi
Journal:  Turk J Haematol       Date:  2020-11-22       Impact factor: 1.831

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.